Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05152394 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Primary and study completion dates: Jan 2026 to Jan 2027
    • Start date changed from estimate of Jan 2022 to Aug 17, 2024
    • Interventions: AlloRx (Biological) to AlloEx (Biological)
    • Study description expanded, about 13 words
    • Site details revised
    • Study title expanded, about 1 word
  2. Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v3
  3. Site contact updatedv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease
Trial Details
NCT Number NCT05152394
Lead Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Conditions
(from sponsor)		 Parkinson Disease
Related terms Parkinson Disease
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov